Can Blood Tests Detect Bone Loss Before a DEXA Scan? | Dr Belinda Beck
Why It Matters
Blood‑based bone turnover markers help track disease activity and therapy response, but they cannot replace DEXA for diagnosing osteoporosis, preserving its central role in clinical decision‑making.
Key Takeaways
- •Blood markers indicate bone turnover but not total bone density.
- •Resorption and formation imbalance drives net bone loss over cycles.
- •Tests can track remodeling activity, not replace DEXA measurements.
- •Elevated resorption markers signal increased bone breakdown risk.
- •Clinicians use markers for monitoring therapy response, not diagnosis.
Summary
The video explores whether blood tests can serve as an early indicator of bone loss before a DEXA scan, with Dr. Belinda Beck explaining the limitations of using serum markers as a surrogate for bone mineral density.
Beck outlines the bone remodeling cycle—osteoclast‑driven resorption and osteoblast‑driven formation—and notes that an imbalance leads to net loss. Blood assays can quantify resorption markers (e.g., CTX) and formation markers (e.g., P1NP), revealing the current turnover rate.
She emphasizes that “the process of remodeling… you get a net loss each remodeling cycle,” and that while a test can detect heightened resorption or formation, it does not tell you how much bone you actually have.
Consequently, clinicians employ these markers to monitor treatment efficacy or disease activity, but DEXA remains the gold standard for diagnosing osteoporosis and guiding therapeutic decisions.
Comments
Want to join the conversation?
Loading comments...